Emerging Pharmacotherapies for Diabetic Macular Edema

<table class="table-group" id="tab4"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td align="left">Agent (# patients)</td><td align="left">Main Outcomes</td><td align="center">Reference</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left">Ruboxistaurin (686)</td><td align="left">Did not meet primary outcome measure at 30  months</td><td align="center">[<a href="/journals/jdr/2012/548732/#B101">102</a>]</td></tr><tr><td align="left">Fenofibrate (9795)</td><td align="left">Favorable outcomes versus placebo at average  of 5 years</td><td align="center">[<a href="/journals/jdr/2012/548732/#B103">104</a>]</td></tr><tr><td align="left">Rosiglitazone (30)</td><td align="left">Some evidence of efficacy at 3 months, but also  may worsen DME in some patients</td><td align="center">[<a href="/journals/jdr/2012/548732/#B106">107</a>]</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Selected Systemic Agents in Treatment of Diabetic Macular Edema.

Journal of Diabetes Research

tab4

Table 4

Table 4: Emerging Pharmacotherapies for Diabetic Macular Edema 